Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 11/17 09:43:03 pm
8.89USD
+4.1%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales1,221,21
EBITDA--62,5
Operating profit (EBIT)-43,8-62,0
Pre-Tax Profit (EBT)-44,1-62,3
Net income-44,1-63,0
EPS ( $ )-3,22-3,08
Dividend per Share ( $ )--
Yield--
Announcement Date03/02/2017
09:05pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance-135
Operating income (EBITDA)--62,5
Leverage
(Debt/EBITDA)
--
Capital Expenditure0,26-
Book Value Per Share (BVPS)-3,75 $
Cash Flow per Share--
Announcement Date03/02/2017
09:05pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 208 M$ -
Entreprise Value (EV) 73,2 M$ 54,7 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS)
Capitalization / Revenue 172x 200x
EV / Revenue 60,4x 52,6x
EV / EBITDA -1,17x -0,76x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,28x 1,74x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) -5 121% -8 126%
operating Leverage (Delta EBIT / Delta Sales) # -2,56x
Net Margin (Net Profit / Revenue) -5 202% -8 295%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -74,7% -65,6%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   - -
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 2,16x 2,15x
BNA & Dividende